Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- The company reported a net loss of $4,151,000 for the year ended March 31, 2024, compared to $5,086,000 in 2023. This change might result in increased investor concern.
- Accumulated deficit increased to $194,349,000 as of March 31, 2024, up from $189,514,000 in 2023. This change indicates worsening financial health.
- The company’s working capital decreased to $8,829,000 as of March 31, 2024, from $10,081,000 in 2023. This change may impact operational flexibility.
- On September 22, 2023, Nasdaq notified the company of non-compliance with minimum bid price of $1. This could lead to delisting, affecting capital access.
- The FDA proposed new regulations for wound dressings, potentially requiring costly compliance for product clearance. This change could significantly impact product marketing timelines.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1367083&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.